Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
A personalized blood test can detect colon cancer recurrence sooner than scans.
Tests for circulating tumor DNA can help predict which patients are more likely to relapse.
In the midst of his testicular cancer journey, Anthony Mastrogiulio found his cancer family.
A simple blood test can reveal treatment response faster than conventional imaging scans.
Some might say that rejoicing over my numbers at this stage is slightly premature.
The blood test identifies biomarkers that could make patients eligible for targeted therapies.
The FoundationOne CDx test identifies solid tumors with NTRK fusions.
“Even though the tests have been around for a while, we don’t know how useful they’re really going to be in the clinical setting."
Guardant360 identifies patients with EGFR mutations, which could guide treatment decisions.
This new test could “play an important role” in screening people who are at risk for developing hepatocellular carcinoma.
A recent study found that blood testing could help with early detection of numerous malignancies.
More than 50 cancers could be discovered, even before symptoms develop.
Tests like the one approved this week can show who is likely to be immune, but it’s not yet clear how long such immunity lasts.
Many people with GI cancers are diagnosed only after the disease has spread through the body, so this test could aid in early detection.
There is evidence that protein patterns can pinpoint propensity for heart disease, liver disease, kidney disease, diabetes and cancer.
A study looked at circulating tumor DNA as a biomarker for health outcomes among women with triple-negative breast cancer.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.